Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue
Research and development collaborations (note 9)	$ 8,269	$ 11,925
Operating expenses:
Research and development	36,526	17,475
General and administrative	7,623	9,003
Total operating expenses	44,149	26,478
Loss from operations	(35,880)	(14,553)
Other income (expense):
Interest income	1,869	1,262
Other income (expenses), net (note 10)	3,250	(157)
Total other income (expense), net	5,119	1,105
Loss before income taxes	(30,761)	(13,448)
Income tax expense	(375)	(193)
Net loss and comprehensive loss	$ (31,136)	$ (13,641)
Net loss per common share (note 4):
Basic and diluted (in dollars per share)	$ (0.64)	$ (0.43)
Weighted-average common shares outstanding (note 4):
Basic and diluted (in shares)	48,686,718	32,020,437